Thursday, November 12, 2026

EUR/CHF Over 1% Down In The Last 10 Sessions

EUR/CHF Over 1% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.01% for the last 10 sessions. At 20:07 EST on Monday, 10 April, EUR/CHF (EURCHF) is $0.99.

EUR/CHF's yearly highs and lows, it's 4.741% up from its 52-week low and 6.068% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.09%, a negative 0.05%, and a positive 0.34%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.25% (last week), 0.35% (last month), and 0.34% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy drives to 132.50 as US employment data supports more rate hikes from fed. According to FXStreet on Monday, 10 April, "The USD/JPY pair has extended its recovery after a nominal correction to 132.50 in the Asian session amid hopes of further escalation in interest rates by the Federal Reserve (Fed). "
  • Usd/jpy price analysis: bulls eye another battle with 50-dma hurdle surrounding 133.00. According to FXStreet on Monday, 10 April, "In a case where the USD/JPY pair remains firmer past 135.20, the Year-To-Date (YTD) high of 137.91 should lure the bulls before highlighting the 140.00 psychological magnet.", "It's worth noting, however, that the 50-DMA hurdle, around 133.20, appears a short-term key challenge for the USD/JPY buyers to pass if they wish to keep the reins."
  • Usd/jpy trims a part of intraday gains to four-day high, holds above 132.00 mark. According to FXStreet on Monday, 10 April, "Reviving bets for further policy tightening by the Federal Reserve (Fed) push the US Dollar (USD) higher for the fourth straight day, which turns out to be a key factor acting as a tailwind for the USD/JPY pair. ", "The USD/JPY pair scales higher for the third successive day on Monday and touched a four-day high, around the 132.80 region, albeit lacks follow-through. "
  • Usd/jpy forecast: buying on dips against yen - 10 April 2023. According to DailyForex on Monday, 10 April, "The USD/JPY pair may experience some downside pressure, with the 50-day exponential moving average acting as the support level. ", "The USD/JPY pair has been hovering around the ¥131 level for some time now, as investors continue to ponder the Bank of Japan's yield curve control measures."
  • Usd/jpy jumps closer to 100 DMA barrier near mid-133.00s amid broad-based USD strength. According to FXStreet on Monday, 10 April, "This will play a key role in influencing the near-term USD price dynamics and help determine the next leg of a directional move for the USD/JPY pair.", "This, in turn, continues to push the USD higher, which, along with dovish-sounding remarks by the new Bank of Japan (BoJ) Governor Kazuo Ueda, prompt aggressive short-covering around the USD/JPY pair."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com